Celgene’s CAR-T Liso-Cel Now in Line for Possible March Approval in Japan

Celgene’s CD19-targeting CAR-T cell therapy lisocabtagene maraleucel (liso-cel/JCAR017) cleared a key advisory panel review on February 17, setting the stage for its approval as early as next month as Japan’s third product in the class. The Pharmaceutical Affairs and Food...read more